Lung Adenocarcinoma Treatment Market
According to Intent Market Research, the Lung Adenocarcinoma Treatment Market is expected to grow from USD 5.7 Billion in 2024-e at a CAGR of 10.8% to touch USD 10.6 Billion by 2030. The Lung Adenocarcinoma Treatment Market is dominated by key players such as, Roche Holding AG, Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, Novartis International AG, and Pfizer Inc.